Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
|
|
Lineage Cell Therapeutics, Inc. (BTX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2023 December 31, 2022 ASSETS CURRENT ASSETS Cash and cash equivalents $ 33,886 $ 11,355 Marketable securities 12,039 46,520 Accounts receivable, net 443 297 Prepaid expenses and other current assets 2,123 1,828 Total current assets 48,491 60,000 NONCURRENT ASSETS Property and equipment, net 5,310 5,673 Deposits and other long-term assets 588 627 Goodwill 10,672 10,672 Intangible assets, net 46,627 46,692 TOTAL ASSETS $ 111,688 $ 123,664 LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 4,685 $ 8,608 Lease liabilities, current portion 933 916 Financing lease, current portion 54 36 Deferred revenues 10,379 9,421 Other current liabilities 1 - Total..." |
|
| 07/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 07/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/11/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 05/18/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/18/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2023 December 31, 2022 ASSETS CURRENT ASSETS Cash and cash equivalents $ 15,451 $ 11,355 Marketable securities 31,363 46,520 Accounts receivable, net 203 297 Prepaid expenses and other current assets 2,638 1,828 Total current assets 49,655 60,000 NONCURRENT ASSETS Property and equipment, net 5,584 5,673 Deposits and other long-term assets 635 627 Goodwill 10,672 10,672 Intangible assets, net 46,659 46,692 TOTAL ASSETS $ 113,205 $ 123,664 LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 5,252 $ 8,608 Lease liabilities, current portion 912 916 Financing lease, current portion 51 36 Deferred revenues 11,009 9,421 Other current liabilities 1 - Tota..." |
|
| 04/27/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/09/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/09/2023 |
8-K
| Quarterly results|
Docs:
|
"LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS December 31, 2022 December 31, 2021 ASSETS CURRENT ASSETS Cash and cash equivalents $ 11,355 $ 55,742 Marketable securities 46,520 2,616 Accounts and grants receivable, net 297 50,840 Prepaid expenses and other current assets 1,828 2,351 Total current assets 60,000 111,549 NONCURRENT ASSETS Property and equipment, net 5,673 4,872 Deposits and other long-term assets 627 630 Goodwill 10,672 10,672 Intangible assets, net 46,692 46,822 TOTAL ASSETS $ 123,664 $ 174,545 LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 8,608 $ 27,969 Lease liabilities, current portion 916 801 Financing lease, current portion 36 30 Deferred revenues 9,421 18,119 Liability classified warra..." |
|
| 01/23/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/10/2022 |
8-K
| Quarterly results |
| 10/31/2022 |
8-K
| Quarterly results |
| 10/28/2022 |
8-K
| Quarterly results |
| 09/30/2022 |
8-K/A
| Quarterly results |
| 09/26/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/11/2022 |
8-K
| Quarterly results |
| 07/08/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/07/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/12/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 04/29/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/29/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/25/2022 |
SC 13D/A
| BROADWOOD PARTNERS, L.P. reports a 20.7% stake in Lineage Cell Therapeutics, Inc. |
| 03/10/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/10/2022 |
8-K
| Quarterly results |
| 02/14/2022 |
8-K
| Other Events Interactive Data |
|
|
|